Careers  |  Sign In  |  Register  |   Twitter

Actos vs Amaryl: Actos Reduces Atherosclerotic Progression

New data stemming from the PERISCOPE trial show intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, Actos reduced the atherosclerotic burden in the coronary arteries compared to Amaryl, and prevented progression compared to baseline.

References and Resources
New data showed Actos prevented progression of atherosclerotic plaque volume in patients.

Sponsored by The Doctor’s Channel